Halozyme Q3 Revenue Jumps 39% to $493M, Full-Year 2026 Guidance Raised
HALO sits 87% above its 52-week low of $61.225.
Summary
Halozyme posted Q3 revenue of $493.0M (+39% YoY) and royalties of $341.0M (+44%), then raised full-year 2026 guidance across revenue, Adjusted EBITDA and EPS.
Key Events · Earnings and Guidance · HALO
-
Q3 Revenue Up 39% to $493M
Total revenue was $493.0M versus $354.3M a year ago, with royalty revenue of $341.0M (+44%) and product sales of $137.3M driving the increase.
-
Full-Year 2026 Guidance Raised
Total revenue guidance moves to $1.860-$1.925B from $1.835-$1.910B, Adjusted EBITDA to $1.240-$1.290B from $1.225-$1.280B, and Non-GAAP diluted EPS to $8.75-$9.05 from $8.65-$9.00.
-
Profitability Scales With Royalties
Operating income reached $295.0M and net income $247.0M; GAAP diluted EPS was $2.01 and Non-GAAP diluted EPS $2.39, versus $1.43 and $1.72 a year ago.
-
Balance Sheet and Buyback
Cash, equivalents, restricted cash and marketable securities totaled $1.08B at September 30, 2026; the company repurchased ~0.8 million shares for $67.2M in Q3 at an average of $79.47, taking 2026 buybacks to $400M.
Analysis · HALO · Life Sciences
Halozyme beat its own trajectory again: Q3 revenue of $493.0M rose 39% year over year and royalties of $341.0M rose 44%, pushing management to lift every full-year line — total revenue to $1.860-$1.925B, Adjusted EBITDA to $1.240-$1.290B and Non-GAAP EPS to $8.75-$9.05. The royalty model is doing the work: partner products like VYVGART Hytrulo, DARZALEX SC and Phesgo keep scaling with little incremental cost, which is why operating income reached $295.0M on $493.0M of revenue. Cash of $1.08B plus $400M of 2026 buybacks and a completed $1.5B convertible raise give room to retire the 2027 and 2028 notes at maturity. The main swing factor outside the numbers is the Dutch court injunction blocking Merck's Keytruda Qlex in eight European markets — a royalty stream that is now protected rather than contested.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HALO was trading at $114.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14B. The 52-week trading range was $61.23 to $134.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.